Boehringer Mannheim (Germany) and Ostex continue to battle
This article was originally published in Clinica
Boehringer Mannheim (Germany) has filed a $20 million damages claim against Ostex for trying to back out of a global partnership. In August, Ostex had terminated a distribution, R&D and licence agreement with Boehringer for the osteoporosis test Osteomark. Ostex is seeking arbitration to confirm the termination (see Clinica No 669/70, p 20).